BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
Despite some controversy over the effectiveness of Gilead Sciences’ Veklury (remdesivir) as the first antiviral drug approved to treat Covid-19, the product is bolstering the company’s bottom line and 2020 guidance was updated to reflect that.
The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.
Incyte and Novartis announced a Phase III study of Jakafi (ruxolitinib), a first-in-class JAK1/JAK2 inhibitor, failed to hit endpoints as a treatment for patients 12 and up with Covid-19 associated cytokine storm.
A single-patient study conducted by British scientists found that Gilead’s remdesivir could be highly effective against Covid-19, raising questions about previous studies that found the antiviral drug had no impact on death rates from the disease.
Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a) on hospitalized patients.
Gilead’s remdesivir should not be used for patients hospitalized with Covid-19, regardless of how ill they are, as there is no evidence the drug improves survival or reduces the need for ventilation, a World Health Organization panel said.
The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.
The antiviral remdesivir should not be used as a routine treatment for Covid-19 patients in critical care wards, the head of one of the world’s top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead.
A World Health Organization-led scheme to supply Covid-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead’s remdesivir therapy, an internal document shows.